<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">phkinetica</journal-id><journal-title-group><journal-title xml:lang="ru">Фармакокинетика и Фармакодинамика</journal-title><trans-title-group xml:lang="en"><trans-title>Pharmacokinetics and Pharmacodynamics</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2587-7836</issn><issn pub-type="epub">2686-8830</issn><publisher><publisher-name>ООО «Издательство ОКИ»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.24411/2587-7836-2019-10036</article-id><article-id custom-type="elpub" pub-id-type="custom">phkinetica-83</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>МЕХАНИЗМ ДЕЙСТВИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>MECHANISM OF ACTION</subject></subj-group></article-categories><title-group><article-title>Подходы к прогнозированию аффинности лигандов 18 кДа транслокаторного белка TSPO с целью создания молекул с нейропсихотропной активностью человека (HUVEC)</article-title><trans-title-group xml:lang="en"><trans-title>Approaches to predict ligands affinity towards translocator protein TSPO 18 kDa in order to create molecules possessing neuropsychotropic activity</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Барабошкин</surname><given-names>Н. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Baraboshkin</surname><given-names>N. M.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Пантилеев</surname><given-names>А. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Pantileev</surname><given-names>A. S.</given-names></name></name-alternatives><email xlink:type="simple">and.pantileev@academpharm.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мокров</surname><given-names>Г. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Mokrov</surname><given-names>G. V.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ «НИИ фармакологии имени В.В. Закусова»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>FSBI «Zakusov Institute of Pharmacology»</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>06</day><month>01</month><year>2019</year></pub-date><volume>0</volume><issue>1</issue><fpage>22</fpage><lpage>30</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Барабошкин Н.М., Пантилеев А.С., Мокров Г.В., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Барабошкин Н.М., Пантилеев А.С., Мокров Г.В.</copyright-holder><copyright-holder xml:lang="en">Baraboshkin N.M., Pantileev A.S., Mokrov G.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.pharmacokinetica.ru/jour/article/view/83">https://www.pharmacokinetica.ru/jour/article/view/83</self-uri><abstract><p>Выполнено прогнозирование аффинности к 18 кДа транслокаторному белку (TSPO) соединений в ряду 1-арилпирроло[1,2-а]пиразин-3-карбоксамидов методами QSAR (Quantitative structure-activity relationship) и молекулярного докинга. Были созданы 9 моделей из комбинации трёх методов машинного обучения (ASNN, FSMLR, PLS) с различным набором 2D фрагментарных дескрипторов (OEState, ISIDA, GSFrag). Для валидации модели использовался 5-кратный перекрёстный контроль. Для молекулярного докинга использовались следующие программы: для построения 3D моделей лигандов программный пакет Marvin от ChemAxon, подготовка белка 2MGY (Protein Data Bank) выполнялась в AutodockTools, а для установления аффинности Autodock 4.2. дополнительно было проведено исследование гидрофобного соответствия в веб-сервисе PLATINUM. В результате данных исследований были выявлены наиболее перспективные лиганды TSPO. Произведён анализ связи структура-аффинность.</p></abstract><trans-abstract xml:lang="en"><p>Predict of anxiolytic activity and affinity for the translocator protein (TSPO), compounds in the 1-arylpyrrolo[1,2-a]pyrazine-3-carboxamide series by QSAR (Quantitative structure-activity relationship) and molecular docking was carried out. 9 Models were created from a combination of three methods of machine learning (ASNN, FSMLR, PLS) with a different set of 2D fragmented descriptors (OEState, ISIDA, GSFrag). For the validation of the model, 5-fold cross-checking was used. For molecular docking, the following programs were used: for building 3D ligand models, Marvin software package from ChemAxon, preparation of protein 2MGY (Protein Data Bank) was performed in AutodockTools, and to establish the affinity of Autodock 4.2. In addition, a study was made of the hydrophobic correspondence in the PLATINUM web service. As a result of these studies, the most promising TSPO ligands were identified. Also, the structure-property relationship was evaluated.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>18 кДа транслокаторный белок TSPO</kwd><kwd>молекулярный докинг</kwd><kwd>QSAR</kwd><kwd>нейропсихотропная активность</kwd><kwd>18 kDa translocator protein TSPO</kwd><kwd>molecular docking</kwd><kwd>QSAR</kwd><kwd>neuropsychotropic activity</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Rupprecht R, Papadopoulos V, Rammes G, et al. Translocator protein (18 kDa)(TSPO) as a therapeutic target for neurological and psychiatric disorders. Nature reviews Drug discovery. 2010;9(12):971. URL: https://doi. org/10.1038/nrd3295.</mixed-citation><mixed-citation xml:lang="en">Rupprecht R, Papadopoulos V, Rammes G, et al. Translocator protein (18 kDa)(TSPO) as a therapeutic target for neurological and psychiatric disorders. Nature reviews Drug discovery. 2010;9(12):971. URL: https://doi. org/10.1038/nrd3295.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Rone MB, Fan J, et al. Cholesterol transport in steroid biosynthesis: role of protein–protein interactions and implications in disease states. Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids. 2009;1791(7):646-658. URL: https://doi.org/10.1016/j.bbalip.2009.03.001.</mixed-citation><mixed-citation xml:lang="en">Rone MB, Fan J, et al. Cholesterol transport in steroid biosynthesis: role of protein–protein interactions and implications in disease states. Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids. 2009;1791(7):646-658. URL: https://doi.org/10.1016/j.bbalip.2009.03.001.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Mokrov GV, Deeva OA, Gudasheva TA, et al. Design, synthesis and anxiolytic-like activity of 1-arylpyrrolo [1, 2-a] pyrazine-3-carboxamides. Bioorganic &amp; medicinal chemistry. 2005;23(13):3368–3378. URL: https:// doi.org/10.1016/j.bmc.2015.04.049</mixed-citation><mixed-citation xml:lang="en">Mokrov GV, Deeva OA, Gudasheva TA, et al. Design, synthesis and anxiolytic-like activity of 1-arylpyrrolo [1, 2-a] pyrazine-3-carboxamides. Bioorganic &amp; medicinal chemistry. 2005;23(13):3368–3378. URL: https:// doi.org/10.1016/j.bmc.2015.04.049</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Verma A, Nye JS, Snyder SH. Porphyrins are endogenous ligands for the mitochondrial (peripheral-type) benzodiazepine receptor. Proceedings of the National Academy of Sciences. 1987;84(8):2256–2260. URL: https:// doi.org/10.1073/pnas.84.8.2256.</mixed-citation><mixed-citation xml:lang="en">Verma A, Nye JS, Snyder SH. Porphyrins are endogenous ligands for the mitochondrial (peripheral-type) benzodiazepine receptor. Proceedings of the National Academy of Sciences. 1987;84(8):2256–2260. URL: https:// doi.org/10.1073/pnas.84.8.2256.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Verleye M, Akwa Y, Liere P, et al. The anxiolytic etifoxine activates the peripheral benzodiazepine receptor and increases the neurosteroid levels in rat brain. Pharmacology Biochemistry and Behavior. 2005;82(4):712–720. URL: https://doi.org/10.1016/j.pbb.2005.11.013.</mixed-citation><mixed-citation xml:lang="en">Verleye M, Akwa Y, Liere P, et al. The anxiolytic etifoxine activates the peripheral benzodiazepine receptor and increases the neurosteroid levels in rat brain. Pharmacology Biochemistry and Behavior. 2005;82(4):712–720. URL: https://doi.org/10.1016/j.pbb.2005.11.013.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Serra M, Madau P, Chessa MF, et al. 2 Phenyl imidazo [1, 2 a] pyridine derivatives as ligands for peripheral benzodiazepine receptors: stimulation of neurosteroid synthesis and anticonflict action in rats. British journal of pharmacology. 1999;127(1):177–187. URL: https://doi.org/10.1038/ sj.bjp.0702530.</mixed-citation><mixed-citation xml:lang="en">Serra M, Madau P, Chessa MF, et al. 2 Phenyl imidazo [1, 2 a] pyridine derivatives as ligands for peripheral benzodiazepine receptors: stimulation of neurosteroid synthesis and anticonflict action in rats. British journal of pharmacology. 1999;127(1):177–187. URL: https://doi.org/10.1038/ sj.bjp.0702530.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang LM, Zhao N, Guo WZ, et al. Antidepressant-like and anxiolyticlike effects of YL-IPA08, a potent ligand for the translocator protein (18 kDa). Neuropharmacology. 2014; 81:116–125. URL: https://doi.org/ 10.1016/j.neuropharm.2013.09.016.</mixed-citation><mixed-citation xml:lang="en">Zhang LM, Zhao N, Guo WZ, et al. Antidepressant-like and anxiolyticlike effects of YL-IPA08, a potent ligand for the translocator protein (18 kDa). Neuropharmacology. 2014; 81:116–125. URL: https://doi.org/ 10.1016/j.neuropharm.2013.09.016.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Da Settimo F, Simorini F, Taliani S, et al. Anxiolytic-like effects of N, N-dialkyl-2-phenylindol-3-ylglyoxylamides by modulation of translocator protein promoting neurosteroid biosynthesis. Journal of medicinal chemistry. 2008;51(18):5798–5806. URL: https://doi.org/10.1021/jm8003224.</mixed-citation><mixed-citation xml:lang="en">Da Settimo F, Simorini F, Taliani S, et al. Anxiolytic-like effects of N, N-dialkyl-2-phenylindol-3-ylglyoxylamides by modulation of translocator protein promoting neurosteroid biosynthesis. Journal of medicinal chemistry. 2008;51(18):5798–5806. URL: https://doi.org/10.1021/jm8003224.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Okuyama S, Chaki S, Yoshikawa R, et al. Neuropharmacological profile of peripheral benzodiazepine receptor agonists, DAA1097 and DAA1106. Life sciences. 1999:64(16):1455–1464. URL: https://doi.org/10.1016/S00243205(99)00079-X.</mixed-citation><mixed-citation xml:lang="en">Okuyama S, Chaki S, Yoshikawa R, et al. Neuropharmacological profile of peripheral benzodiazepine receptor agonists, DAA1097 and DAA1106. Life sciences. 1999:64(16):1455–1464. URL: https://doi.org/10.1016/S00243205(99)00079-X.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Gavioli EC, Duarte FS, Bressan, E, et al. Antidepressant-like effect of Ro5-4864, a peripheral-type benzodiazepine receptor ligand, in forced swimming test. European journal of pharmacology. 2003;471(1):21–26. URL: https://doi.org/10.1016/S0014-2999(03)01789-8.</mixed-citation><mixed-citation xml:lang="en">Gavioli EC, Duarte FS, Bressan, E, et al. Antidepressant-like effect of Ro5-4864, a peripheral-type benzodiazepine receptor ligand, in forced swimming test. European journal of pharmacology. 2003;471(1):21–26. URL: https://doi.org/10.1016/S0014-2999(03)01789-8.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Ryu, JK, Choi HB, et al. Peripheral benzodiazepine receptor ligand PK11195 reduces microglial activation and neuronal death in quinolinic acid-injected rat striatum. Neurobiology of disease. 2005;20(2):550–561. URL: https://doi.org/10.1016/j.nbd.2005.04.010.</mixed-citation><mixed-citation xml:lang="en">Ryu, JK, Choi HB, et al. Peripheral benzodiazepine receptor ligand PK11195 reduces microglial activation and neuronal death in quinolinic acid-injected rat striatum. Neurobiology of disease. 2005;20(2):550–561. URL: https://doi.org/10.1016/j.nbd.2005.04.010.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Mitsui K, Niwa T, Kawahara Y, et al. Anti-stress effects of ONO-2952, a novel translocator protein 18 kDa antagonist, in rats. Neuropharmacology. 2015;99:51–66. URL: https://doi.org/10.1016/j.neuropharm.2015.07.011.</mixed-citation><mixed-citation xml:lang="en">Mitsui K, Niwa T, Kawahara Y, et al. Anti-stress effects of ONO-2952, a novel translocator protein 18 kDa antagonist, in rats. Neuropharmacology. 2015;99:51–66. URL: https://doi.org/10.1016/j.neuropharm.2015.07.011.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Li XB, Guo HL, Shi TY, et al. Neuroprotective effects of a novel translocator protein (18 kD a) ligand, ZBD 2, against focal cerebral ischemia and NMDA induced neurotoxicity. Clinical and Experimental Pharmacology and Physiology. 2015;42(10):1068–1074. URL: https://doi.org/10.1111/14401681.12460.</mixed-citation><mixed-citation xml:lang="en">Li XB, Guo HL, Shi TY, et al. Neuroprotective effects of a novel translocator protein (18 kD a) ligand, ZBD 2, against focal cerebral ischemia and NMDA induced neurotoxicity. Clinical and Experimental Pharmacology and Physiology. 2015;42(10):1068–1074. URL: https://doi.org/10.1111/14401681.12460.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">URL: https://www.fda.gov/</mixed-citation><mixed-citation xml:lang="en">URL: https://www.fda.gov/</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Hamon A, Morel A, Hue B, et al. The modulatory effects of the anxiolytic etifoxine on GABAA receptors are mediated by the subunit. Neuropharmacology. 2003;45(3):293–303. URL: https://doi.org/10.1016/ S0028-3908(03)00187-4.</mixed-citation><mixed-citation xml:lang="en">Hamon A, Morel A, Hue B, et al. The modulatory effects of the anxiolytic etifoxine on GABAA receptors are mediated by the subunit. Neuropharmacology. 2003;45(3):293–303. URL: https://doi.org/10.1016/ S0028-3908(03)00187-4.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Free SM, et al. A mathematical contribution to structure-activity studies. Journal of Medicinal Chemistry. 1964;7(4):395–399. URL: https:// doi.org/10.1021/jm00334a001</mixed-citation><mixed-citation xml:lang="en">Free SM, et al. A mathematical contribution to structure-activity studies. Journal of Medicinal Chemistry. 1964;7(4):395–399. URL: https:// doi.org/10.1021/jm00334a001</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Mitra I, Saha A, et al. Predictive modeling of antioxidant coumarin derivatives using multiple approaches: descriptor-based QSAR, 3D-pharmacophore mapping, and HQSAR. Scientia pharmaceutica. 2002;81(1):57–80. URL: https://doi.org/10.3797/scipharm.1208-01.</mixed-citation><mixed-citation xml:lang="en">Mitra I, Saha A, et al. Predictive modeling of antioxidant coumarin derivatives using multiple approaches: descriptor-based QSAR, 3D-pharmacophore mapping, and HQSAR. Scientia pharmaceutica. 2002;81(1):57–80. URL: https://doi.org/10.3797/scipharm.1208-01.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Gramatica P. Principles of QSAR models validation: internal and external. QSAR &amp; combinatorial science. 2007;26(5):694–701. URL: https:// doi.org/10.1002/qsar.200610151.</mixed-citation><mixed-citation xml:lang="en">Gramatica P. Principles of QSAR models validation: internal and external. QSAR &amp; combinatorial science. 2007;26(5):694–701. URL: https:// doi.org/10.1002/qsar.200610151.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Irwin JJ, Sterling T, Mysinger MM, et al. ZINC: a free tool to discover chemistry for biology. Journal of chemical information and modeling. 2012;52(7):1757–1768. URL: https://doi.org/10.1021/ci3001277.</mixed-citation><mixed-citation xml:lang="en">Irwin JJ, Sterling T, Mysinger MM, et al. ZINC: a free tool to discover chemistry for biology. Journal of chemical information and modeling. 2012;52(7):1757–1768. URL: https://doi.org/10.1021/ci3001277.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Sushko I, Novotarskyi S, K rner R, et al. Online chemical modeling environment (OCHEM): web platform for data storage, model development and publishing of chemical information. Journal of Computer-Aided Molecular Design. 2011;25(6):533–554. URL: https://doi.org/10.1007/s10822-011-9440-2.</mixed-citation><mixed-citation xml:lang="en">Sushko I, Novotarskyi S, K rner R, et al. Online chemical modeling environment (OCHEM): web platform for data storage, model development and publishing of chemical information. Journal of Computer-Aided Molecular Design. 2011;25(6):533–554. URL: https://doi.org/10.1007/s10822-011-9440-2.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Jaremko Ł, Jaremko M, Giller K, et al. Structure of the mitochondrial translocator protein in complex with a diagnostic ligand. Science. 2014;343(6177):1363–1366. URL: https://doi.org/10.1126/science.1248725.</mixed-citation><mixed-citation xml:lang="en">Jaremko Ł, Jaremko M, Giller K, et al. Structure of the mitochondrial translocator protein in complex with a diagnostic ligand. Science. 2014;343(6177):1363–1366. URL: https://doi.org/10.1126/science.1248725.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Kreisl WC, Jenko K J, Hines CS, et al. A genetic polymorphism for translocator protein 18 kDa affects both in vitro and in vivo radioligand binding in human brain to this putative biomarker of neuroinflammation. Journal of Cerebral Blood Flow &amp; Metabolism. 2013;33(1):53–58. URL: https:// doi.org/10.1038%2Fjcbfm.2012.131.</mixed-citation><mixed-citation xml:lang="en">Kreisl WC, Jenko K J, Hines CS, et al. A genetic polymorphism for translocator protein 18 kDa affects both in vitro and in vivo radioligand binding in human brain to this putative biomarker of neuroinflammation. Journal of Cerebral Blood Flow &amp; Metabolism. 2013;33(1):53–58. URL: https:// doi.org/10.1038%2Fjcbfm.2012.131.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Morris GM, Huey R, Lindstrom W, et al. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. Journal of computational chemistry. 2009;30(16):2785–2791. URL: https:// doi.org/10.1002/jcc.21256.</mixed-citation><mixed-citation xml:lang="en">Morris GM, Huey R, Lindstrom W, et al. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. Journal of computational chemistry. 2009;30(16):2785–2791. URL: https:// doi.org/10.1002/jcc.21256.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Gasteiger, J., &amp; Marsili, M. (1980). Iterative partial equalization of orbital electronegativity—a rapid access to atomic charges. Tetrahedron, 36(22), 3219–3228. URL: https://doi.org/10.1016/0040-4020(80)80168-2.</mixed-citation><mixed-citation xml:lang="en">Gasteiger, J., &amp; Marsili, M. (1980). Iterative partial equalization of orbital electronegativity—a rapid access to atomic charges. Tetrahedron, 36(22), 3219–3228. URL: https://doi.org/10.1016/0040-4020(80)80168-2.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Lipinski CA. Lead-and drug-like compounds: the rule-of-five revolution. Drug Discovery Today: Technologies. 2004;1(4):337–341. URL: https://doi.org/10.1016/j.ddtec.2004.11.007.</mixed-citation><mixed-citation xml:lang="en">Lipinski CA. Lead-and drug-like compounds: the rule-of-five revolution. Drug Discovery Today: Technologies. 2004;1(4):337–341. URL: https://doi.org/10.1016/j.ddtec.2004.11.007.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Hansch C, Rockwell SD, Jow PY, et al. Substituent constants for correlation analysis. Journal of medicinal chemistry. 1977;20(2):304–306. URL: https://doi.org/10.1021/jm00212a024.</mixed-citation><mixed-citation xml:lang="en">Hansch C, Rockwell SD, Jow PY, et al. Substituent constants for correlation analysis. Journal of medicinal chemistry. 1977;20(2):304–306. URL: https://doi.org/10.1021/jm00212a024.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
